Consider the peculiar career of a donated liver. It has somewhere to be, almost no patience for delays, and a medical team working against the clock. OrganOx built a machine that keeps it functioning outside the body. In February 2025, HealthQuest Capital led a $142 million financing for the company. By October, Terumo had completed its acquisition for approximately $1.5 billion.
- HealthQuest backs healthcare businesses ready to expand commercially.
- Its practical question: can a useful innovation win adoption and make economic sense?
- OrganOx shows the opportunity. Inbound Health shows the exposure to financing and policy.
That sequence is tempting to read as a story about spotting a clever invention. Look closer. At the financing announcement, OrganOx’s technology had already been used in more than 5,000 liver transplants. HealthQuest arrived at a business with clinical use and international approvals. The assignment was expansion. In healthcare, that can be an investment problem quite different from discovery.
A doctor follows the money
Garheng Kong trained as a physician, scientist and engineer, collecting an MD, PhD and MBA at Duke after studying at Stanford. His explanation for becoming an investor contains a wonderfully practical observation: “nothing went from bench to bedside without capital.” Money, in that account, belongs inside the medical story.
The founding group brought complementary experience. Randy Scott, who joined Kong in starting HealthQuest in 2013, had built NovaMin Technology and worked on the early LensCrafters team. David Kabakoff, the founding senior partner, had helped develop diagnostic products including rapid pregnancy and strep tests. These were people familiar with turning a scientific capability into something another person could actually use.
The patient isn’t always the buyer
HealthQuest’s territory stretches across medical devices, diagnostics, healthcare IT, services and pharma services. Its stated primary target is commercial-stage companies ready to scale. Growth Equity and Tactical Opportunities give it different ways to supply capital. The portfolio is organized around a healthcare problem and its commercial prospects, rather than a requirement that every answer take the same technological form.
This distinction matters because healthcare has an awkward buying arrangement. The person who benefits from a product, the person who uses it and the organization paying for it can be three different parties. Kong described those competing incentives in the 2022 Fund IV announcement. A persuasive pitch must travel through all three perspectives.
“there is a natural tension between patients, providers and payers”
Garheng Kong / Fund IV announcement, 2022
The firm surrounds its investment team with operating partners, an Industry Advisory Board and a Healthcare IT Council. The current roster includes former leaders of Medtronic, Becton Dickinson and LabCorp, alongside health-system technology executives. The practical appeal is straightforward: people who understand how healthcare organizations work can ask uncomfortable commercial questions before expansion makes those questions expensive.
Industry access is also part of the competition. LRVHealth, an overlapping healthcare investor whose portfolio includes Diana Health and hellocare.ai, builds its model around strategic healthcare organizations. HealthQuest therefore has to offer more than introductions. Its combination of operating backgrounds, flexible capital strategies and sector breadth is the package a founder would compare. The sensible question is specific: which investor understands this company’s next difficult decision?
What the capital actually buys
HealthQuest serves two constituencies. Limited partners commit money to its funds. Management teams receive investment and support. Fund III’s investors included financial institutions, pensions, strategic healthcare organizations, foundations and family offices across the US, Europe and Asia. This is private investment management, with portfolio ownership and eventual liquidity at the center of the business.
The fundraising numbers describe the scale of that work: Fund II closed at $225 million in 2016, Fund III at $440 million in 2019, and Fund IV at $675 million in 2022. Those are commitments to investment funds. They should not be read as revenue earned by the firm or a price tag on HealthQuest itself.
For OrganOx, the financing announcement described growth opportunities for its metra platform. The machine preserves donor livers in a metabolically active state and allows assessment before transplantation. The commercial proposition reaches beyond a device’s engineering: it addresses the practical difficulty of making donor organs available and usable. Terumo subsequently bought the company. HealthQuest’s individual check and proceeds cannot be inferred from those headline figures.
Two billion dollars. Carefully read.
HistoSonics supplies another example. Its Edison system uses focused ultrasound to mechanically destroy targeted tissue. An August 2025 announcement described a management-led majority acquisition valuing the company at approximately $2.25 billion. HealthQuest was among its existing investors. At that point, the company reported more than 2,000 patients treated at over 50 US medical centers.
The attraction is visible: a technology progressing into clinical use, then attracting capital for further expansion. Still, a company transaction valuation tells us little about any one investor’s purchase price, ownership or net return. It is evidence of a market transaction. Reading it as a complete investment scorecard would skip most of the arithmetic.
The hospital-at-home counterexample
In September 2023, HealthQuest led Inbound Health’s $30 million Series B. Inbound helped health systems deliver advanced care at home. The financing was intended for expansion and development of clinical programs, technology and operating capabilities. It was an intelligible bet on moving care into a different setting.
Inbound later shut down. Public reporting linked the closure to financing difficulties and uncertainty around the federal hospital-at-home program. MedArrive acquired technology assets in March 2026. The lesson is uncomfortable and useful: a care model can offer clinical and operational benefits while remaining vulnerable to the rules and funding that support delivery.
Bring the budget case with the clinical case
The portfolio keeps widening. In September 2026, HealthQuest participated in Thyme Care’s more than $125 million Series E, backing a company coordinating cancer care across patients, providers and health plans. That sits comfortably beside organ preservation: different work, the same concern with how care reaches people.
A founder can borrow that discipline without borrowing a dollar. Identify who benefits, who must change their working day and who signs the payment. Test all three. HealthQuest’s approach fits companies with something ready to deliver and a credible route to wider use. Unproven science, fragile payment assumptions or expansion without workable economics demand a different conversation. The invention earns attention. Getting it used earns the next meeting.